ENGN
enGene Holdings Inc.
Biotechnology
Market Cap$83M
5Y Perf.-78.9%
Build Your Comparison
Side-by-side financial analysisENGN
RCKT
Try popular comparisons:
Stock Comparison
ENGN vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$300M
5Y Perf.-88.2%
ENGN vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ENGN |  RCKT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $83M | $300M |
| Revenue (TTM) | — | $0.00 |
| Net Income (TTM) | $-122M | $-209M |
| Total Debt | $32M | $25M |
| Cash & Equiv. | $50M | $78M |
ENGN vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ENGN
RCKT
| Stock | Nov 23 | Jun 26 | Return |
|---|---|---|---|
| enGene Holdings Inc. (ENGN) | 100 | 21.1 | -78.9% |
| Rocket Pharmaceutic… (RCKT) | 100 | 11.8 | -88.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ENGN vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RCKT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. enGene Holdings Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇RCKT emerged as the overall leader. Track its performance:
ENGN
enGene Holdings Inc.
The Quality Compounder
ENGN is the clearest fit if your priority is quality and efficiency.
- 2.9% margin vs RCKT's 2.6%
- -45.7% ROA vs RCKT's -59.6%, ROIC -67.4% vs -62.4%
Best for: quality and efficiency
RCKT
Rocket Pharmaceuticals, Inc.
The Income Pick
RCKT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 2.06
- EPS growth 26.4%
- -91.1% 10Y total return vs ENGN's -91.9%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  RCKT | 19.7% revenue growth vs ENGN's -77.3% |
| Quality / Margins |  ENGN | 2.9% margin vs RCKT's 2.6% |
| Stability / Safety | RCKT | Beta 2.06 vs ENGN's 2.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RCKT | -10.4% vs ENGN's -50.2% |
| Efficiency (ROA) | ENGN | -45.7% ROA vs RCKT's -59.6%, ROIC -67.4% vs -62.4% |
ENGN vs RCKT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRCKTLAGGINGENGN
ENGNenGene Holdings Inc.
0leads
RCKTRocket Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs ENGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCKT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RCKT5/6
Risk & VolatilityBeta, volatility, and downside exposure
RCKT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCKT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
| Metric | ENGNenGene Holdings I… | RCKTRocket Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | — | $0 |
| EBITDAEarnings before interest/tax | -$127M | -$206M |
| Net IncomeAfter-tax profit | -$122M | -$209M |
| Free Cash FlowCash after capex | -$104M | -$180M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +8.3% | +25.0% |
RCKT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ENGN and RCKT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ENGNenGene Holdings I… | RCKTRocket Pharmaceut… |
|---|---|---|
| Market CapShares × price | $83M | $300M |
| Enterprise ValueMkt cap + debt − cash | $65M | $248M |
| Trailing P/EPrice ÷ TTM EPS | -0.71x | -1.37x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.49x | 1.10x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ENGN and RCKT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — ENGN and RCKT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
ENGN delivers a -55.8% return on equity — every $100 of shareholder capital generates $-56 in annual profit, vs $-71 for RCKT. RCKT carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENGN's 0.19x.
| Metric | ENGNenGene Holdings I… | RCKTRocket Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -55.8% | -70.8% |
| ROA (TTM)Return on assets | -45.7% | -59.6% |
| ROICReturn on invested capital | -67.4% | -62.4% |
| ROCEReturn on capital employed | -50.7% | -58.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 0.19x | 0.09x |
| Net DebtTotal debt minus cash | -$18M | -$53M |
| Cash & Equiv.Liquid assets | $50M | $78M |
| Total DebtShort + long-term debt | $32M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -40.18x | -43.58x |
Evenly matched — ENGN and RCKT each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RCKT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ENGN five years ago would be worth $810 today (with dividends reinvested), compared to $582 for RCKT. Over the past 12 months, RCKT leads with a -10.4% total return vs ENGN's -50.2%. The 3-year compound annual growth rate (CAGR) favors RCKT at -50.7% vs ENGN's -56.7% — a key indicator of consistent wealth creation.
| Metric | ENGNenGene Holdings I… | RCKTRocket Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -81.7% | -20.5% |
| 1-Year ReturnPast 12 months | -50.2% | -10.4% |
| 3-Year ReturnCumulative with dividends | -91.9% | -88.0% |
| 5-Year ReturnCumulative with dividends | -91.9% | -94.2% |
| 10-Year ReturnCumulative with dividends | -91.9% | -91.1% |
| CAGR (3Y)Annualised 3-year return | -56.7% | -50.7% |
RCKT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
RCKT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RCKT is the less volatile stock with a 2.06 beta — it tends to amplify market swings less than ENGN's 2.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCKT currently trades 50.5% from its 52-week high vs ENGN's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ENGNenGene Holdings I… | RCKTRocket Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.26x | 2.06x |
| 52-Week HighHighest price in past year | $12.25 | $5.45 |
| 52-Week LowLowest price in past year | $1.40 | $2.40 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +50.5% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 31.1 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 2.3M |
RCKT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ENGN as "Hold" and RCKT as "Buy". Consensus price targets imply 332.1% upside for ENGN (target: $7) vs 81.8% for RCKT (target: $5).
| Metric | ENGNenGene Holdings I… | RCKTRocket Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $7.00 | $5.00 |
| # AnalystsCovering analysts | 9 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCKT leads in 3 of 6 categories — strongest in Income & Cash Flow and Total Returns. 2 categories are tied.
Best OverallRocket Pharmaceuticals, Inc. (RCKT)Leads 3 of 6 categories
Loading custom metrics...
ENGN vs RCKT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ENGN or RCKT a better buy right now?
Analysts rate Rocket Pharmaceuticals, Inc.
(RCKT) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ENGN or RCKT?
Over the past 5 years, enGene Holdings Inc.
(ENGN) delivered a total return of -91. 9%, compared to -94. 2% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: RCKT returned -91. 1% versus ENGN's -91. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ENGN or RCKT?
By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.
(RCKT) is the lower-risk stock at 2. 06β versus enGene Holdings Inc. 's 2. 26β — meaning ENGN is approximately 10% more volatile than RCKT relative to the S&P 500. On balance sheet safety, Rocket Pharmaceuticals, Inc. (RCKT) carries a lower debt/equity ratio of 9% versus 19% for enGene Holdings Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ENGN or RCKT?
On earnings-per-share growth, the picture is similar: Rocket Pharmaceuticals, Inc.
grew EPS 26. 4% year-over-year, compared to -56. 8% for enGene Holdings Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ENGN or RCKT?
enGene Holdings Inc.
(ENGN) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Rocket Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENGN leads at 0. 0% versus 0. 0% for RCKT. At the gross margin level — before operating expenses — ENGN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ENGN or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ENGN or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.
(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. enGene Holdings Inc. (ENGN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCKT: -91. 1%, ENGN: -91. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ENGN and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.